RxDoctor Payments Data

David Karaffa, MD

Neurology · Palm Coast, FLNPI 1528048147

Payments from drug & device makers

$111in general payments, 2019–2025

Across 6 payments — averaging $18.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Microtransponder, Inc.$28
  • Sunovion Pharmaceuticals Inc.$23
  • AbbVie$19
  • Argenx US, Inc.$14
  • Silk Road Medical, Inc.$14
  • Lilly USA, LLC$11

What the payments were for

  • Food & beverage$111100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Microtransponder, Inc.1$28
Sunovion Pharmaceuticals Inc.1$23
AbbVie1$19
Argenx US, Inc.1$14
Silk Road Medical, Inc.1$14
Lilly USA, LLC1$11

How this compares

$111 in reported general payments places this provider in the 15th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$133,574
Medicare patients
559
Services billed
1,054

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BetaseronInterferon Beta-1b12$119,822
Aimovig AutoinjectorErenumab-Aooe32$29,558
QuliptaAtogepant11$20,209
GlatopaGlatiramer Acetate13$19,281
RexultiBrexpiprazole13$17,479
Nurtec OdtRimegepant Sulfate11$16,997
Oxtellar XrOxcarbazepine12$15,917
EliquisApixaban15$11,953
Gabapentin445$10,590
Memantine Hcl227$10,235
Levetiracetam266$10,171
Lacosamide35$8,737
Oxcarbazepine124$5,693
Rivastigmine14$5,284
Carbidopa-LevodopaCarbidopa/Levodopa129$4,263

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta$19$20,20911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 1,434 neurology providers in Florida.

Other neurology in Palm Coast

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →